United Therapeutics (UTHR) Stock Still Looks Like A Bargain After A 185% Run

Simply Wall St.07-18

United Therapeutics stock has delivered a strong 5 year run, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched, even as recent insider selling and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652280519?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-18 03:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652280519","market":"us","top_or_hot":-1,"title":"United Therapeutics (UTHR) Stock Still Looks Like A Bargain After A 185% Run","media":"Simply Wall St.","content":"<div>\n<p>United Therapeutics stock has delivered a strong 5 year run, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched, even as recent insider selling and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-uthr-stock-still-looks-like-a-bargain-af\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics (UTHR) Stock Still Looks Like A Bargain After A 185% Run</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics (UTHR) Stock Still Looks Like A Bargain After A 185% Run\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-18 03:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-uthr-stock-still-looks-like-a-bargain-af><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>United Therapeutics stock has delivered a strong 5 year run, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched, even as recent insider selling and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-uthr-stock-still-looks-like-a-bargain-af\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1699723380.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-uthr-stock-still-looks-like-a-bargain-af","article_id":"2652280519","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-uthr-stock-still-looks-like-a-bargain-af","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652280519","pubTimestamp":1784315946,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"United Therapeutics stock has delivered a strong 5 year run, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched, even as recent insider selling and fresh clinical and regulatory news give investors more to weigh.\n\nUnited Therapeutics has returned 184.8% over the past 5 years, which puts extra focus on whether the current share price still reflects a reasonable entry point after such a long period of gains.\nRecent FDA approval for the LungFX...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4139":"生物科技","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4532":"文艺复兴科技持仓","UTHR":"美国联合医疗"},"translate_title":"United Therapeutics (UTHR) 股票在上涨 185% 后看起来仍然很便宜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics stock has delivered a strong 5 year run, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched, even as recent insider selling and fresh clinical and regulatory news give investors more to weigh.  United Therapeutics has returned 184.8% over the past 5 years, which puts extra focus on whether the current share price still reflects a reasonable entry point after such a long period of gains. Recent FDA approval for the LungFX device and positive phase 3 data for nebulized Tyvaso can support expectations for future cash flows, while the chief executive's recent US$5.2m stock sale may prompt some shareholders to question how much upside is already reflected in the price. On Simply Wall St's broader checks, United Therapeutics screens as undervalued in 5 of 6 areas, which suggests the overall valuation picture still tilts toward the stock looking cheap rather than expensive.  The issue now is whether that combination of strong long term returns and a high value score leaves enough margin for error for new investors at today's price. United Therapeutics delivered 77.9% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementIs United Therapeutics Still Cheap on Earnings? The P/E multiple is a relevant metric for United Therapeutics because the company is generating positive earnings and trades on a well-established market track record. United Therapeutics currently trades on a P/E of about 17.4x, which is close to the broader biotech industry average of 17.1x and below the peer group average of 20.3x. That places the stock roughly in line with the sector overall, while still at a discount to similar companies in the peer set. The fair P/E suggested by the model, which adjusts for factors such as margins, size and risk, is 25.4x. Compared with the current 17.4x, that indicates the market is assigning a lower multiple than this framework suggests. Despite the recent LungFX approval and positive Tyvaso phase 3 data increasing interest in United Therapeutics, the earnings multiple remains below both the modelled fair level and the peer average. On the P/E yardstick, United Therapeutics stock currently appears undervalued. NasdaqGS:UTHR P/E Ratio as at Jul 2026 See what the numbers say about this price — find out in our valuation breakdown. The United Therapeutics Narrative: What Would Justify Today's Price? Simply Wall St Narratives for United Therapeutics pick up where the P/E discussion leaves off by explaining which combinations of future growth, margins and earnings would need to hold for United Therapeutics' stock to be worth meaningfully more or less than it is today. Instead of stopping at a single output from a ratio or model, they show the underlying path that number relies on and give you something concrete to monitor over time on the Community page. Community views on United Therapeutics sit far apart, with some investors focused on long runway potential and others worried about concentration risk and future competition. Bull case: 29% undervalued \"United Therapeutics' unmatched leadership and real-world progress in groundbreaking technologies like xenotransplantation and organ manufacturing expose the company to entirely new, uncrowded multibillion-dollar markets...\" Read the full Bull Case to see why United Therapeutics could be undervalued Bear case: roughly fairly valued \"While United Therapeutics has experienced sustained revenue growth fueled by Tyvaso DPI and a concentrated portfolio, this heavy reliance on a small number of key drugs exposes the company to severe patent expiration and generic/biosimilar risk over the long term...\" Read the full Bear Case to see why United Therapeutics could be overvalued Do you think there's more to the story for United Therapeutics? Head over to our Community to see what others are saying! The Bottom Line United Therapeutics still screens as undervalued on earnings, with its current P/E sitting below both the peer group and the fair multiple suggested by broader checks. That discount sits alongside active product news and insider selling, which point in different directions for sentiment. For you, the key question is whether United Therapeutics can sustain the earnings profile that justifies a re rating or whether concentration and competitive risks mean the current multiple is closer to where it should be. The answer to that tension, rather than past returns, is what will matter most from here.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652280519","isCrawlerRequest":true}